Evidence map›Paper›PMID 39829377›Full record

Observational studyImmunotherapy2025

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.

Matilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Nicola Simoni, Eleonora Lai, Marco Maruzzo, Umberto Basso and 20 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Matilde CorianòDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Alessandro LazzarinDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Michele MaffezzoliDepartment of Medicine and Surgery, University of Parma, Parma, Italy.ORCID 0000-0001-7877-8988
Matteo SantoniOncology Unit, Macerata Hospital, Macerata, Italy.
Giulia MazzaschiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Sara RodellaMedical Oncology Unit, University of Brescia, Brescia, Italy.
Nicola SimoniRadiotherapy Unit, University Hospital of Parma, Parma, Italy.
Eleonora LaiOncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Marco MaruzzoOncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Umberto BassoOncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Davide BimbattiOncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Roberto IacovelliMedical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
Annunziato AngheloneMedical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
Ondřej FialaDepartment of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
Sara Elena RebuzziMedical Oncology Unit, Ospedale San Paolo institution, Savona, Italy.
Giuseppe FornariniDepartment of Oncology and Hematology, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Cristian LolliDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Francesco MassariMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Matteo RoselliniMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Veronica MollicaMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Cecilia NassoMedical Oncology, Ospedale Santa Corona, Pietra Ligure, Italy.
Alessandro AcunzoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Enrico Maria SiliniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Federico QuainiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Massimo De FilippoDepartment of Medicine and Surgery, Section of Radiology, University of Parma, Parma, Italy.
Matteo BrunelliDepartment of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Giuseppe L BannaDepartment of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
Pasquale RescignoTranslational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
Alessio SignoriSection of biostatistics, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Sebastiano ButiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.ORCID 0000-0003-0876-0226

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). MATERIALS AND

methodsWe performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations.

resultsThree hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter.

conclusionHb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice.

Indexed as

Carcinoma, Renal CellHemoglobinsImmune Checkpoint InhibitorsImmunotherapyKidney NeoplasmsAdultAgedAged, 80 and overErythrocyte IndicesFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesHemoglobinsImmune Checkpoint Inhibitorshemoglobinimmune checkpoint inhibitorsmetastatic renal cell carcinomaNLRPrognostic scoreratioRDWtyrosine-kinase inhibitors

Identifiers

PMID39829377
PMCPMC12551330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.